OPCU Special Edition: Peptides & Oligos

This interactive roundtable brought together industry experts to explore the unique challenges of outsourcing peptide drug development with CDMOs and CMOs. The conversation highlights critical pain points across the development journey, including:

– Synthesis & Scale-Up: The technical complexity of moving from lab-scale peptide synthesis to commercial volumes while managing yield, purity, and cost.
– Analytical Hurdles: The difficulty of establishing robust testing methods for increasingly complex peptides, from characterization and stability to impurity profiling.
– Regulatory Requirements: How evolving global expectations demand early alignment between sponsors and outsourcing partners to avoid costly delays.

Participants share best practices for effective CDMO collaboration, lessons on pitfalls to avoid, and emerging innovations reshaping the outsourcing landscape, such as advances in continuous flow synthesis, new analytical platforms, and strategies for improving scalability and compliance.